Ekambar Kandimalla

Title: Ekambar Kandimalla: Innovator in Spherical Nucleic Acids

Introduction

Ekambar Kandimalla is a notable inventor based in Skokie, IL (US). He has made significant contributions to the field of biotechnology, particularly in the development of spherical nucleic acids (SNA). With a total of 2 patents, his work focuses on innovative methods for targeted therapies.

Latest Patents

Kandimalla's latest patents include groundbreaking inventions. One patent is titled "Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA." This invention relates to antisense oligonucleotides directed to the interleukin 17 receptor (IL-17R) and other targets. It also provides spherical nucleic acid formulations or compositions of antisense oligonucleotides and related methods of treatment. Another patent is "Synthesis of spherical nucleic acids using lipophilic moieties." This patent describes spherical nucleic acids (SNA) carrying self-aggregating oligonucleotides, including compositions of the SNA that consist of discrete nanostructures that are not aggregated.

Career Highlights

Kandimalla is currently associated with Exicure Operating Company, where he continues to advance his research and innovations. His work has positioned him as a key figure in the biotechnology sector, contributing to the development of novel therapeutic approaches.

Collaborations

He collaborates with notable colleagues, including Richard Kang and Scott Mix, who share his vision for advancing biotechnological innovations.

Conclusion

Ekambar Kandimalla's contributions to the field of spherical nucleic acids and targeted therapies highlight his role as an influential inventor. His patents reflect a commitment to advancing medical science through innovative solutions.